Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Romilkimab in IPF
NCT01529853Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2012
- Primary completion
- Oct 2013
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of romilkimab in idiopathic pulmonary fibrosis (IPF), sponsored by Sanofi. Started Jan 2012; status: completed.
02
Drugs
romilkimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01529853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01529853.